Logo

AstraZeneca's Bevespi Aerosphere (glycopyrronium/formoterol fumarate) Receives NMPA's Approval for Patients with COPD

Share this

AstraZeneca's Bevespi Aerosphere (glycopyrronium/formoterol fumarate) Receives NMPA's Approval for Patients with COPD

Shots:

  • The NMPA’s approval is based on P-III PINNACLE 4 study assessing Bevespi Aerosphere (bid via a pMDI) vs its monotherapy components (glycopyrronium and formoterol fumarate) and PBO in patients with moderate to very severe COPD
  • The P-III PINNACLE 4 study demonstrated improvement in lung function as measured by trough forced expiratory volume in one second (FEV1)- published in the International Journal of Chronic Obstructive Pulmonary Disease
  • The approval follows the approval of AstraZeneca’s triple-combination therapy- Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) for the maintenance treatment of COPD in China. Bevespi Aerosphere (FD) is a dual bronchodilator- administered in a pressurized metered-dose inhaler utilizing Aerosphere delivery technology

Click here ­to­ read full press release/ article 

Ref: AstraZeneca | Image: AstraZeneca 

 


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions